Core Viewpoint - Goldman Sachs reports encouraging updates on the Phase II data for DQ Biotech-B (06996) in the treatment of unresectable or metastatic gastric cancer (GC) [1] Group 1: Drug Development and Regulatory Approval - DQ Biotech's ATG-022 has received breakthrough therapy designation from the National Medical Products Administration for treating CLDN18.2 positive, HER2 negative unresectable or metastatic gastric cancer or gastroesophageal junction adenocarcinoma (GC/GEJ) patients [1] - The company presented Phase II dose expansion data from the CLINCH study for ATG-022 in treating advanced and metastatic solid tumors, indicating competitive efficacy and safety due to increased patient numbers and extended follow-up time [1] Group 2: Financial Outlook - Goldman Sachs raised the target price for DQ Biotech from HKD 2.61 to HKD 2.99, reflecting an enhanced competitive position for ATG-022 in gastric cancer treatment, leading to increased sales forecasts for the coming years [1] - The firm believes that the median progression-free survival (mPFS) will be a key focus for future updates, which may directly impact competitor comparisons and the visibility of potential accelerated approval pathways [1]
高盛：升德琪医药-B目标价至2.99港元 ATG-022竞争力加强